KR20230127926A - Composition for antioxidant effects containing an extract of polar microalgae as an active ingredient - Google Patents

Composition for antioxidant effects containing an extract of polar microalgae as an active ingredient Download PDF

Info

Publication number
KR20230127926A
KR20230127926A KR1020230024869A KR20230024869A KR20230127926A KR 20230127926 A KR20230127926 A KR 20230127926A KR 1020230024869 A KR1020230024869 A KR 1020230024869A KR 20230024869 A KR20230024869 A KR 20230024869A KR 20230127926 A KR20230127926 A KR 20230127926A
Authority
KR
South Korea
Prior art keywords
extract
composition
cell line
microalgae
antioxidant effect
Prior art date
Application number
KR1020230024869A
Other languages
Korean (ko)
Inventor
정윤재
임윤희
김상희
김은재
Original Assignee
가천대학교 산학협력단
한국해양과학기술원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가천대학교 산학협력단, 한국해양과학기술원 filed Critical 가천대학교 산학협력단
Publication of KR20230127926A publication Critical patent/KR20230127926A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

본 발명은 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물에 관한 것으로, 더욱 상세하게는 사람의 장상피세포주와 각질세포주를 이용하여 극지 미세조류 추출물의 특이적 영향 분석을 통해 장관과 피부의 염증 질환을 조절하고, 항산화 효과가 우수한 조성물을 제공하는 것에 관한 것이다.
본 발명에 따른 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물은, 장상피 세포와 각질세포내 과산화수소(H2O2)를 유의적으로 감소시켜 세포내 항산화 효과가 있고, 장관과 피부의 염증 질환을 조절하는 효과가 있다.The present invention relates to a composition for antioxidant effect comprising an extract of polar microalgae as an active ingredient, and more particularly, by analyzing the specific effect of the extract of polar microalgae using a human intestinal epithelial cell line and a keratinocyte line, the intestinal It relates to providing a composition that controls inflammatory diseases of the skin and has an excellent antioxidant effect.
The composition for antioxidant effect comprising an extract of polar microalgae according to the present invention as an active ingredient has an intracellular antioxidant effect by significantly reducing hydrogen peroxide (H 2 O 2 ) in intestinal epithelial cells and keratinocytes, It is effective in controlling inflammatory diseases of the skin and skin.

Description

극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물{COMPOSITION FOR ANTIOXIDANT EFFECTS CONTAINING AN EXTRACT OF POLAR MICROALGAE AS AN ACTIVE INGREDIENT}Composition for antioxidant effect containing an extract of polar microalgae as an active ingredient

본 발명은 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물에 관한 것으로, 더욱 상세하게는 사람의 장상피세포주와 각질세포주를 이용하여 극지 미세조류 추출물의 특이적 영향 분석을 통해 장관과 피부의 염증 질환을 조절하고, 항산화 효과가 우수한 조성물을 제공하는 것에 관한 것이다.The present invention relates to a composition for antioxidant effect comprising an extract of polar microalgae as an active ingredient, and more particularly, by analyzing the specific effect of the extract of polar microalgae using a human intestinal epithelial cell line and a keratinocyte line, the intestinal It relates to providing a composition that controls inflammatory diseases of the skin and has an excellent antioxidant effect.

최근 염증성 장질환 뿐 아니라 장관 외부의 질환에서도 장관 면역계 이상이 보고되고 있다. 건선은 염증성 장질환 동반 비율이 높으며 장관투과도 증가 및 마이크로바이옴 불균형이 확인되었다(JAMA Dermatol 154:1417). 다발성 경화증 중증도는 장관투과도와 유의하게 연관되어 있으며, 장점막 장벽기능 손상시 신경탈수초화가 증가한다(Brain 141:1900).Recently, intestinal immune system abnormalities have been reported not only in inflammatory bowel disease but also in diseases outside the intestinal tract. Psoriasis has a high comorbidity with inflammatory bowel disease, and increased intestinal permeability and microbiome imbalance have been confirmed (JAMA Dermatol 154:1417). Multiple sclerosis severity is significantly related to intestinal permeability, and nerve demyelination increases when intestinal barrier function is impaired (Brain 141:1900).

염증성 질환의 증가원인으로 서구식 식단의 유입 및 영양분의 과도한 섭취에 의한 장관 점막 손상 및 투과성 증가가 제시되고 있다. 대사이상, 심혈관질환 등의 합병증까지 고려하였을 때 염증성 질환 범주에 속하는 질환의 발병 빈도는 5명 중 1명에 달해, 향후 국가 보건의 중대한 위험 요소로 치료제 시장 규모는 세계적으로 60조원 이상으로 예상된다.Damage to the intestinal mucosa and increased permeability due to the influx of a Western diet and excessive intake of nutrients have been proposed as the cause of the increase in inflammatory diseases. Considering complications such as metabolic abnormalities and cardiovascular diseases, the frequency of occurrence of diseases belonging to the category of inflammatory diseases reaches 1 in 5 cases. .

염증성 장질환 치료에 비특이적 염증 억제제와 단일 표적 염증매개체를 억제하는 생물학적 제제가 이용되고 있지만, 발병과 관련된 단백질, 사이토카인, 대사체 등이 다양하기 때문에 하나의 대사과정이나 신호전달과정, 타깃 단백질 조절로 완벽한 치료효과를 획득하는 것은 어려운 실정이다.Biological agents that inhibit non-specific inflammation inhibitors and single-target inflammatory mediators are used for the treatment of inflammatory bowel disease. However, it is difficult to obtain a perfect therapeutic effect.

생물학적 제제는 70% 정도의 환자에서만 반응이 있고, 장기간 사용시 약물에 대한 항체 형성으로 치료효과가 감소하거나 장점막 장벽 유지에 필요한 정상 면역반응이 억제되어 역설적 장질환이 발생할 수 있다(N Engl J Med 376:1551, J Invest Dermatol 135:31).Biological agents respond to only about 70% of patients, and when used for a long time, the therapeutic effect may be reduced due to the formation of antibodies to the drug or the normal immune response required to maintain the intestinal barrier may be suppressed, resulting in paradoxical intestinal disease (N Engl J Med 376 :1551, J Invest Dermatol 135:31).

피부와 장관의 염증 질환을 근원적으로 조절하기 위해서는 상피 및 점막의 장벽 기능 강화가 필수적이다.In order to fundamentally control inflammatory diseases of the skin and intestinal tract, it is essential to strengthen the barrier function of the epithelial and mucous membranes.

극지 생물은 극한의 환경에서 효율적으로 생존하기 위해 일반 생물체와 구별되는 세포보호물질을 생산할 것으로 예상되어, 장벽 구조물을 경계로 외부 환경에 직접 노출되어 있는 피부와 장관의 면역 불균형 조절을 위한 천연물 신물질로서 활용 가능성이 높아 다양한 연구가 필요한 실정이다.Polar organisms are expected to produce cell protective substances that are distinct from normal organisms in order to survive in extreme environments efficiently, and as a new natural substance for controlling immune imbalance in the skin and intestinal tract directly exposed to the external environment across the barrier structure. There is a high possibility of utilization, and various studies are needed.

등록특허공보 10-2054391Registered Patent Publication 10-2054391

본 발명의 목적은 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물을 제공하는 데 있다.An object of the present invention is to provide a composition for antioxidant effect comprising an extract of polar microalgae as an active ingredient.

상기 목적을 달성하기 위하여, 본 발명은 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for antioxidant effect comprising an extract of polar microalgae as an active ingredient.

상기 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물은, 서열번호 2 내지 6으로 이루어진 군에서 선택된 1종 이상의 미세조류의 추출물을 유효성분으로 포함할 수 있다.The composition for an antioxidant effect comprising an extract of polar microalgae as an active ingredient may include an extract of one or more types of microalgae selected from the group consisting of SEQ ID NOs: 2 to 6 as an active ingredient.

상기 세포는 Caco-2 장상피세포주와 HaCaT 각질세포주일 수 있다.The cells may be a Caco-2 intestinal epithelial cell line and a HaCaT keratinocyte cell line.

상기 Caco-2 장상피세포주와 HaCaT 각질세포주는 미세조류를 Caco-2 장상피세포주와 HaCaT 각질세포주에 상기 미세조류의 추출물이 0.5 내지 1.5 ug/ml 농도로 15 내지 20시간 동안 처리된 것일 수 있다.The Caco-2 intestinal epithelial cell line and the HaCaT keratinocyte cell line may be prepared by treating microalgae with the microalgae extract at a concentration of 0.5 to 1.5 ug/ml for 15 to 20 hours. .

상기 Caco-2 장상피세포주와 HaCaT 각질세포주는, ROS(reactive oxygen species) 유도물질로서, 과산화수소(H2O2)로 처리된 것일 수 있다.The Caco-2 intestinal epithelial cell line and the HaCaT keratinocyte cell line may be treated with hydrogen peroxide (H 2 O 2 ) as a reactive oxygen species (ROS) inducer.

본 발명에 따른 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물은, 장상피 세포와 각질세포내 과산화수소(H2O2)를 유의적으로 감소시켜 세포내 항산화 효과가 있고, 장관과 피부의 염증 질환을 조절하는 효과가 있다.The composition for antioxidant effect comprising an extract of polar microalgae according to the present invention as an active ingredient has an intracellular antioxidant effect by significantly reducing hydrogen peroxide (H 2 O 2 ) in intestinal epithelial cells and keratinocytes, It is effective in controlling inflammatory diseases of the skin and skin.

도 1은 미세조류 추출물(1 ug/ml)을 전처치 후 과산화수소(H2O2)를 첨가(250 mM)했을 때 장상피 세포내 항산화능 측정 결과를 나타낸 그래프이다.
도 2는 미세조류 추출물(1 ug/ml)을 전처치 후 과산화수소(H2O2)를 첨가(250 mM)했을 때 각질세포 세포내 항산화능 측정 결과를 나타낸 그래프이다.1 is a graph showing the results of measuring the antioxidant activity in intestinal epithelial cells when hydrogen peroxide (H 2 O 2 ) was added (250 mM) after pretreatment with a microalgae extract (1 ug/ml).
Figure 2 is a graph showing the results of measuring the antioxidant capacity of keratinocyte cells when hydrogen peroxide (H 2 O 2 ) was added (250 mM) after pretreatment with microalgae extract (1 ug/ml).

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명의 일 형태에 따라 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물을 제공한다.According to one aspect of the present invention, there is provided a composition for an antioxidant effect comprising an extract of polar microalgae as an active ingredient.

상기 극지 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물은, 서열번호 2 내지 6으로 이루어진 군에서 선택된 1종 이상의 미세조류의 추출물을 유효성분으로 포함할 수 있다.The composition for an antioxidant effect comprising an extract of polar microalgae as an active ingredient may include an extract of one or more types of microalgae selected from the group consisting of SEQ ID NOs: 2 to 6 as an active ingredient.

상기 세포는 Caco-2 장상피세포주와 HaCaT 각질세포주일 수 있다.The cells may be a Caco-2 intestinal epithelial cell line and a HaCaT keratinocyte cell line.

상기 Caco-2 장상피세포주와 HaCaT 각질세포주는, 미세조류를 Caco-2 장상피세포주와 HaCaT 각질세포주에 상기 미세조류의 추출물이 0.5 내지 1.5 ug/ml 농도로 15 내지 20시간 동안 처리된 것일 수 있다.The Caco-2 intestinal epithelial cell line and the HaCaT keratinocyte cell line may be prepared by treating the microalgae with the microalgae Caco-2 intestinal epithelial cell line and the HaCaT keratin cell line at a concentration of 0.5 to 1.5 ug/ml for 15 to 20 hours. there is.

상기 Caco-2 장상피세포주와 HaCaT 각질세포주는, ROS(reactive oxygen species) 유도물질로서, 과산화수소(H2O2)로 처리된 것일 수 있다.The Caco-2 intestinal epithelial cell line and the HaCaT keratinocyte cell line may be treated with hydrogen peroxide (H 2 O 2 ) as a reactive oxygen species (ROS) inducer.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.

본 발명에서는 서열번호 1 내지 6 중에서 선택된 각각의 서열번호를 갖는 6 가지 극지 미세조류 KNM0029C(서열번호 1), KSF0015(서열번호 2), KSF0037(서열번호 3), KSF0003(서열번호 4), KSF0134(서열번호 5) 및 KSF0041(서열번호 6)에 대해 항산화 효과를 분석하였다.In the present invention, six polar microalgae KNM0029C (SEQ ID NO: 1), KSF0015 (SEQ ID NO: 2), KSF0037 (SEQ ID NO: 3), KSF0003 (SEQ ID NO: 4), KSF0134 having each SEQ ID NO selected from SEQ ID NOS: 1 to 6 (SEQ ID NO: 5) and KSF0041 (SEQ ID NO: 6) were analyzed for antioxidant effects.

실시예 1. 극지 미세조류 추출물의 ROS(reactive oxygen species) 영향 평가Example 1. ROS (reactive oxygen species) effect evaluation of polar microalgae extract

도 1은 미세조류 추출물(1 ug/ml)을 전처치 후 과산화수소(H2O2)를 첨가(250 mM)했을 때 장상피 세포내 항산화능 측정 결과를 나타낸 그래프이다. 사람의 장상피세포주(Caco-2)에 미세조류 KSF0041, KNM0029C, KSF0015, KSF0037, KSF0003 및 KSF0134를 1 ug/ml 농도로 18시간 동안 전처치한 후 독성이 강한 ROS 유도물질의 일종인 과산화수소(H2O2)를 처리하였다. 항산화능을 측정한 결과, KNM0029C, KSF0015, KSF0037, KSF0003 및 KSF0134를 처리한 경우, 장상피 세포내 H2O2를 유의적으로 감소시켜 세포내 항산화능을 입증하였다.1 is a graph showing the results of measuring the antioxidant activity in intestinal epithelial cells when hydrogen peroxide (H 2 O 2 ) was added (250 mM) after pretreatment with a microalgae extract (1 ug/ml). Human intestinal epithelial cell line (Caco-2) was pretreated with microalgae KSF0041, KNM0029C, KSF0015, KSF0037, KSF0003 and KSF0134 at a concentration of 1 ug/ml for 18 hours, and hydrogen peroxide (H 2 O 2 ) was treated. As a result of measuring antioxidant capacity, when KNM0029C, KSF0015, KSF0037, KSF0003 and KSF0134 were treated, H 2 O 2 in intestinal epithelial cells was significantly reduced, proving intracellular antioxidant capacity.

*: vs. H2O2, **P < 0.01, ***P < 0.001, ****P < 0.0001, (oneway ANOVA)*: vs. H 2 O 2 , **P < 0.01, ***P < 0.001, ****P < 0.0001, (oneway ANOVA)

도 2는 미세조류 추출물(1 ug/ml)을 전처치 후 과산화수소(H2O2)를 첨가(250 mM)했을 때 각질 세포내 항산화능 측정 결과를 나타낸 그래프이다. 사람의 각질세포주(HaCaT)에 미세조류 KSF0041, KNM0029C, KSF0015, KSF0037, KSF0003 및 KSF0134를 1 ug/ml 농도로 18시간 동안 전처치한 후 독성이 강한 ROS 유도물질의 일종인 과산화수소(H2O2)를 처리하였다. 항산화능을 측정한 결과, KSF0003, KSF0015, KSF0037, KSF0041 및 KSF0134를 처리한 경우, 각질 세포내 H2O2를 유의적으로 감소시켜 세포내 항산화능을 입증하였다.Figure 2 is a graph showing the results of measuring the antioxidant capacity in keratinocytes when hydrogen peroxide (H 2 O 2 ) was added (250 mM) after pretreatment with microalgae extract (1 ug/ml). Human keratinocytes (HaCaT) were pretreated with microalgae KSF0041, KNM0029C, KSF0015, KSF0037, KSF0003 and KSF0134 at a concentration of 1 ug/ml for 18 hours, and hydrogen peroxide (H 2 O 2 , a type of highly toxic ROS inducer) ) was treated. As a result of measuring the antioxidant capacity, when KSF0003, KSF0015, KSF0037, KSF0041 and KSF0134 were treated, H 2 O 2 in keratinocytes was significantly reduced, demonstrating intracellular antioxidant capacity.

*: vs. H2O2, ***P < 0.001, ****P < 0.0001, (oneway ANOVA)*: vs. H 2 O 2 , ***P < 0.001, ****P < 0.0001, (oneway ANOVA)

이상, 본 발명내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.In the above, specific parts of the present invention have been described in detail, and for those skilled in the art, it is clear that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. something to do. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (4)

서열번호 1 내지 5로 이루어진 군에서 선택된 1종 이상의 미세조류의 추출물을 유효성분으로 포함하는 항산화 효과를 위한 조성물.A composition for antioxidant effect comprising an extract of at least one microalgae selected from the group consisting of SEQ ID NOs: 1 to 5 as an active ingredient. 제1항에 있어서,
상기 항산화 효과는 Caco-2 장상피세포주와 HaCaT 각질세포주에서 나타나는 것을 특징으로 하는 항산화 효과를 위한 조성물.According to claim 1,
The antioxidant effect is a composition for an antioxidant effect, characterized in that it appears in the Caco-2 intestinal epithelial cell line and the HaCaT keratinocyte cell line. 제2항에 있어서,
상기 Caco-2 장상피세포주와 HaCaT 각질세포주는 Caco-2 장상피세포주와 HaCaT 각질세포주에 상기 미세조류의 추출물이 0.5 내지 1.5 ug/ml 농도로 15 내지 20시간 동안 처리된 것을 특징으로 하는 항산화 효과를 위한 조성물.According to claim 2,
The Caco-2 intestinal epithelial cell line and the HaCaT keratinocyte cell line are treated with the extract of the microalgae at a concentration of 0.5 to 1.5 ug/ml for 15 to 20 hours to the Caco-2 intestinal epithelial cell line and the HaCaT keratin cell line Antioxidant effect, characterized in that composition for. 제2항에 있어서,
상기 Caco-2 장상피세포주와 HaCaT 각질세포주는, ROS(reactive oxygen species) 유도물질로서, 과산화수소(H2O2)로 처리된 것을 특징으로 하는 항산화 효과를 위한 조성물.
According to claim 2,
The Caco-2 intestinal epithelial cell line and the HaCaT keratinocyte cell line, as a reactive oxygen species (ROS) inducer, are treated with hydrogen peroxide (H 2 O 2 ) A composition for an antioxidant effect, characterized in that.
KR1020230024869A 2022-02-24 2023-02-24 Composition for antioxidant effects containing an extract of polar microalgae as an active ingredient KR20230127926A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220024391 2022-02-24
KR20220024391 2022-02-24

Publications (1)

Publication Number Publication Date
KR20230127926A true KR20230127926A (en) 2023-09-01

Family

ID=87975294

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020230024869A KR20230127926A (en) 2022-02-24 2023-02-24 Composition for antioxidant effects containing an extract of polar microalgae as an active ingredient

Country Status (1)

Country Link
KR (1) KR20230127926A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102054391B1 (en) 2018-06-28 2019-12-11 한국해양과학기술원 Composition for Preventing or Treating Inflammation or Cancer Containing Extract of Micractinium sp.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102054391B1 (en) 2018-06-28 2019-12-11 한국해양과학기술원 Composition for Preventing or Treating Inflammation or Cancer Containing Extract of Micractinium sp.

Similar Documents

Publication Publication Date Title
Lehrer et al. Nonoxidative fungicidal mechanisms of mammalian granulocytes: demonstration of components with candidacidal activity in human, rabbit, and guinea pig leukocytes
Brosch et al. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum.
Noble Skin microbiology: coming of age
Cousin et al. Altered macrophage‐like functions of preadipocytes in inflammation and genetic obesity
EP1162968B1 (en) Epigallocatechin-gallate for inhibiting angiogenesis
Kantengwa et al. Phagocytosis of Staphylococcus aureus induces a selective stress response in human monocytes-macrophages (M phi): modulation by M phi differentiation and by iron
CN110590914B (en) Honey and polypeptide composition for inhibiting and eliminating helicobacter pylori biofilm formation
Akaza et al. Effects of Propionibacterium acnes on various mRNA expression levels in normal human epidermal keratinocytes in vitro
Blanchaer et al. Isozymes of lactic dehydrogenase in skeletal muscle
Gilbert et al. SPARC gene expression is reduced in early diabetes-related kidney growth
KR20230127926A (en) Composition for antioxidant effects containing an extract of polar microalgae as an active ingredient
CN113908097A (en) Acne-removing composition and application thereof
CN116286543A (en) Staphylococcus epidermidis with good moisturizing, whitening, anti-inflammatory, antioxidant and anti-aging effects and application thereof
Wu et al. Mechanistic basis for loss of water balance in green tree frogs infected with a fungal pathogen
Dutta et al. Anticlastogenic effect of redistilled cow's urine distillate in human peripheral lymphocytes challenged with manganese dioxide and hexavalent chromium
CN115414287B (en) Composition with oil control and moisturizing effects and application thereof
Zheng et al. Novel organic selenium source hydroxy-selenomethionine counteracts the blood-milk barrier disruption and inflammatory response of mice under heat stress
JP4753922B2 (en) Raw materials for cosmetics
DE102014113861B4 (en) Bioactive component for use in combating lung tumor metastasis
Galgiani et al. Effects of adenylate cyclase toxin from Bordetella pertussis on human neutrophil interactions with Coccidioides immitis and Staphylococcus aureus
Pellissari et al. Statherin-derived peptides as antifungal strategy against Candida albicans
EP3478302A1 (en) Preparation with the viable mycoparasitic microorganism pythium oligandrum for the treatment of dermaphytoses and yeast infections on the skin and mucous membranes, method of determining the cell&#39;s viability of the microorganism pythium oligandrum and method of applying the preparation
DE60310212T2 (en) Use of a hydrogen peroxide-producing enzyme for the treatment of otitis media
KR102264354B1 (en) Composition for improving skin conditions
KR20230127413A (en) Composition for cell viability containing an extract of polar microalgae as an active ingredient